Indication
Retinal Dystrophies
5 clinical trials
4 products
Product
MCO-010Clinical trial
A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE StudyStatus: , Estimated PCD: 2027-07-01
Clinical trial
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")Status: Active (not recruiting), Estimated PCD: 2025-05-23
Product
EDIT-101Clinical trial
The Effects of Disulfiram on Visual Acuity in Patients With Retinal DegenerationStatus: Not yet recruiting, Estimated PCD: 2025-04-15
Product
DisulfiramClinical trial
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal DystrophyStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Product
VP-001